CompletedNCT00320489
Long-acting olanzapine injections or tablets for schizophrenia
About this title
Read the official source — NCT00320489Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Escondido and 48 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 524
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Canada, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00320489
- Official title
Show the full official title
A Randomized, Open-label Study Comparing the Effects of Olanzapine Pamoate Depot With Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Escondido, United States · National City, United States · Orange, United States
46 more locations
- San Diego, United States
- Washington D.C., United States
- Honolulu, United States
- Chicago, United States
- Cedarhurst, United States
- Staten Island, United States
- Canton, United States
- Allentown, United States
- Philadelphia, United States
- West Chester, United States
- Banfield, Argentina
- Buenos Aires, Argentina
- Mendoza, Argentina
- Pelotas, Brazil
- Rio de Janeiro, Brazil
- São Paulo, Brazil
- Calgary, Canada
- Winnipeg, Canada
- Burlington, Canada
- Chatham, Canada
- Greater Sudbury, Canada
- Montreal, Canada
- Dijon, France
- Dole, France
- La Seyne-sur-Mer, France
- Limoges, France
- Strasbourg, France
- Toulon, France
- Chaïdári, Greece
- Haidari, Athens, Greece
- Thessaloniki, Greece
- Tripoli, Greece
- Lisbon, Portugal
- Cabo Rojo, Puerto Rico
- Caguas, Puerto Rico
- Mayagüez, Puerto Rico
- Rio Piedras, Puerto Rico
- Bucharest, Romania
- Iași, Romania
- Târgu Mureş, Romania
- Bratislava, Slovakia
- Alzira, Spain
- Barcelona, Spain
- Hua-Lian County, Taiwan
- Taipei, Taiwan
- Taoyuan City, Taiwan
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including olanzapine and olanzapine pamoate depot.
Who was this study for?
Listed age limits: 18 years to 65 years.
